

# metabolytix

The Continuous Metabolic Monitoring Platform



a **CANCER FUND** portfolio company  
**VENTURE LABS**

# WHY CANCER FUND IS INVESTING IN METABOLYTIX

CANCER FUND invests in innovations with potential to impact patients, survivors, and at-risk populations



## An Immediate Community Need:

~14% of chemotherapy patients experience Acute Kidney Injury (AKI); up to ~50% for certain types of cancer\*



## Aligns with Our Impact Goals:

Reduce AKI in chemo patients



## Part of Our Management & Prevention Strategy:

High frequency low-cost monitoring and diagnostics



## A Viable Impact Investment Opportunity:

Fits our investment plan, criteria, and target returns

**CANCER FUND supports Metabolytix to reduce AKI Cancer Patients**

# MARKET OPPORTUNITIES IN ONCOLOGY AND COMORBIDITIES

Basic Metabolic Panel (BMP) data is a key component of medical diagnosis and treatment in healthcare

In 2019, Medicare Part B Reimbursed 7,059,894 BMP tests (CPT CODE: 80048)

	Oncology	Cardiology	Renal Care	General Healthcare
Application	Monitoring and diagnosis during therapeutic treatment	Monitoring kidney function during titration of medication	Monitoring renal system performance during diagnosis and treatment	Monitoring and tracking key metabolic measures during hospitalization and treatment
# of Tests Annually	~850,000 tests/ year	~130,000 test/ year	~42,000 tests/ year	~225,000 tests/ year

Today's methods of collecting BMP data enable but don't facilitate treatment Real Time

# TODAY'S BASIC METABOLIC PANEL (BMP)

## Blood Draws, Lab Processing, and Physician Review Disrupts Patient Lives

1

**Painful**

Requires  
Blood Draw

2

**Slow**

Requires Lab  
Processing

3

**Costly**

\$120-180  
In-Hospital Test  
(CPT 80061)

4

**Infrequent**

Single Time  
Point Test

5

**Inaccessible**

Requires staffed  
hospital, labs,  
clinics

### **BMP Measures**

Potassium	BUN
Sodium	Creatinine
Chloride	Calcium
Bicarbonates	Glucose

### **BMP Assesses:**

- Fluid balance electrolytes
- Metabolism
- Liver and kidney function
- Acid/base balance
- Blood glucose

**Today's BMP negatively impacts patient outcomes**

# CONTINUOUS BMP (cBMP) COULD IMPROVE OUTCOMES

More Frequent cBMP Offers Convenience to Patients, Improved Data for Providers, Lower Cost for Payers

## Patient Benefits

- Convenient Wearable Device
- No Blood Draw - Reduced Lab Visits
- High Test Frequency > Improved Outcomes

## Provider Benefits


- Simplified Hospital Operation
- Automated data collection and monitoring with Real Time Results

## Payer Benefits

- \$500 Pricing : Targeting 66% less than current methods (Based on 3 tests per day for 3 day hospitalization, 9 tests total)

## Broad Applicability

- In-patient
- Outpatient
- At Home Care and Mobile Care



Metabolytix focus is continuous BMP (cBMP)

# OUR PRODUCT ROADMAP: Addressing a Series of Needs

Better Treatment, Improved Patient Experience, and Targeting Lower Cost


Timing	2026		2030	2032
Market Opportunity	Oncology: AKI for chemo patients	Cardiology + Renal: Cardio-Renal Syndrome	TBD: Multiple Opportunities	General Healthcare / Wellness
Product	Cardio-Renal Analyte Monitor (CRAM)		CRAM +2 additional analytes	Full cBMP
Capabilities	Creatinine (Cr) Potassium (K) Glucose (Glu)		CRAM (Cr, K, GLU) Plus 2 of:  Carbon Dioxide (CO2) Blood Urea Nitrogen (BUN) Calcium (Ca) Chloride (Cl) Sodium (Na)	Creatinine (Cr) Potassium (K) Glucose (Glu) Carbon Dioxide (CO2) Blood Urea Nitrogen (BUN) Calcium (Ca) Chloride (Cl) Sodium (Na)

Metabolytix Will Focus on High Impact, Limited Applications and Expand Analytes Over Time


# OUR PRODUCT ROADMAP: Addressing a Series of Needs

## Metabolytix Plans A Sequential and Additive Product Roadmap


**CRAM  
(2026)**



**CRAM+2  
(2030)**



**cBMP  
(2032)**



**Targeting Minimum  
Viable Product  
Launch in 2026**


## MARKET OPPORTUNITIES

	CRAM	CRAM+2	cBMP
 Oncology	✓		
 Cardiology	✓		
 Renal Care	✓		
 Sleep Disorders		✓	
 Weight Loss		✓	
 Gen'l Healthcare			✓
 Wellness			✓
 Fitness			✓

# OUR VALUE PROPOSITION

Improving Outcomes, Reducing Costs Across the Patient and Survivor Journey

## The Patient Journey





# OUR CORE ASSET

## Our Team

### EXECUTIVE TEAM



**Anthony Bajoras**  
**CEO, Co-Founder**

CANCER FUND Founder and Managing Director; BioAccel board member, managing their health innovation investment fund.

20+ years of early-stage experience as a founder, executive, consultant, advisor, and investor, including sensor enabled wearables, medical device, bioinformatics, pharmaceutical, wellness, and healthcare IT/IoT ventures.

5 years leading MedTech Ventures venture studio, incubator, and accelerator program design, development, launch, and deliver.

BS in Business Management & Entrepreneurship from DePaul University; non-degree undergraduate and graduate studies in design, engineering, and business from ASU, Illinois Institute of Technology, and Northwestern Univ.



**Jeff La Belle, PhD**  
**CTO, Co-Founder**

LaBelle Labs Founder and research professor of 20+ yrs: Grand Canyon University; ASU, Mayo Clinic College of Medicine; and National Academy of Inventors member.

Research: noninvasive sensing, point-of-care, advanced manufacturing technology.

Projects: PoC and continuous implantable electrochemical impedance spectroscopy insulin sensor; diabetes biomarker multi-sensors; non-invasive glucose sensors; multifunction HDL/LDL or intercellular change sensors detecting cancers; pharmaceutical level sensors enabling dose modulation; continuous wearable stress sensors; and embeddable sensors.

B.S. an M.S. in Electrical Engineering from Western New England University and his M.S. and Ph.D. in Bioengineering from Arizona State University.



**Ben Trapp**  
**VP Product, Co-Founder**

Desert Bloom Innovations Founder with 24 years in medical device product innovation at W.L. Gore

7 years as Medical Division Front End Innovation Leader managing portfolio and \$20M fund.

10 years of med device product development engineering and management experience.

24 granted patents and 10 filed patent applications, including: multi-sensor treatments systems; tethering for implantable biosensors; and implantable cardiac sensors.

BS in Materials Engineering and graduate studies in Biomaterials & Fibers, Drexel University.

### PRODUCT TEAM



**Jake Snyder**  
Product management, project management



**Jeff Rea**  
Market research, validating user needs and use cases.

### ADVISORS



**John Grant, PhD**  
Business development and strategic partnerships.  
CEO and founder of Lemnos Advisory

33+ years at 3M: general management; strategy; mergers/ acquisitions/ alliances; Int'l BD; commercialization.


PhD, Northwestern Univ.; MBA, Univ. of Minnesota



**Andy Teague**  
Market development and clinical concept validation.

# WHERE WE ARE, WHERE WE'RE GOING.

## Metabolytix Is Entering the Innovation Phase to Progress Toward First-in-Man Application



**WE ARE HERE.**

Our research phase is (nearly) complete.

We are readying to move into the Innovation Phase.

**The Next Major Milestone: First in Man for our Continuous Cardio-Renal Analyte Monitor (CRAM)**

# HOW WE GET THERE:

## Key Innovation Phase Activities

### Key Innovation Stage Milestones Have Been Established



#### Technology

Validation  
Licensing



#### Market

Select Clinical Partners



#### Reimbursement

Quantify Value Proposition  
Quantify Cost Effectiveness  
Reimbursement Strategy



#### Product

Proof of concept Prototyping  
Integration for Manufacturability



#### Team

Expand Engineering Team

# cBMP: The Next Stage of Continuous Metabolic Monitoring

Today's BMP is an obstacle to telemedicine delivery, cBMP enables telemedicine for tomorrow

Improvements in BMP enabled by advancing technologies;  
Metabolytix: highly focused on cBMP


Today's BMP works but has not kept pace with dynamic technology changes

Current BMP is an obstacle to telemedicine delivery and more effective treatment of patients

Metabolytix founding team is strong and well positioned in the Phoenix MedTech Ecosystem

cBMP is an attractive market opportunity with long runway.

Now is the time for Metabolytix



Note: individuals of any age who use wired or wireless devices that remotely track or collect well-being or medical data from the user outside a traditional healthcare setting at least once per month, and exchange it via the internet with electronic health records accessed by a medical professional or healthcare provider; includes wearable devices, home health devices, and sensors

Source: Insider Intelligence, Aug 2021

269585

InsiderIntelligence.com

By 2022, 45.1 million US patients will use RPM tools. Insider Intelligence

**Metabolytix: Enabling the future of medicine, health, wellness, and wellbeing.**

## CONTACT

Anthony Bajoras

*CEO, Co-Founder*



*The Continuous Metabolic Monitoring Platform*

*anthony@metabolytix.com*

*602-821-1500*